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A B S T R A C T   
Background: Frontotemporal dementia (FTD) is a common cause of young onset dementia, and whilst there are 
currently no treatments, there are several promising candidates in development and early phase trials. 
Comprehensive investigations of neuroimaging markers of disease progression across the full spectrum of FTD 
disorders are lacking and urgently needed to facilitate these trials. 
Objective: To investigate the comparative performance of multiple automated segmentation and registration 
pipelines used to quantify longitudinal whole-brain atrophy across the clinical, genetic and pathological sub-
groups of FTD, in order to inform upcoming trials about suitable neuroimaging-based endpoints. 
Methods: Seventeen fully automated techniques for extracting whole-brain atrophy measures were applied and 
directly compared in a cohort of 226 participants who had undergone longitudinal structural 3D T1-weighted 
imaging. Clinical diagnoses were behavioural variant FTD (n = 56) and primary progressive aphasia (PPA, n 
= 104), comprising semantic variant PPA (n = 38), non-fluent variant PPA (n = 42), logopenic variant PPA (n =
18), and PPA-not otherwise specified (n = 6). 49 of these patients had either a known pathogenic mutation or 
postmortem confirmation of their underlying pathology. 66 healthy controls were included for comparison. 
Sample size estimates to detect a 30% reduction in atrophy (80% power; 0.05 significance) were computed to 
explore the relative feasibility of these brain measures as surrogate markers of disease progression and their 
ability to detect putative disease-modifying treatment effects. 
Results: Multiple automated techniques showed great promise, detecting significantly increased rates of whole- 
brain atrophy (p<0.001) and requiring sample sizes of substantially less than 100 patients per treatment arm. 
Across the different FTD subgroups, direct measures of volume change consistently outperformed their indirect 
counterparts, irrespective of the initial segmentation quality. Significant differences in performance were found 
between both techniques and patient subgroups, highlighting the importance of informed biomarker choice 
based on the patient population of interest. 
Conclusion: This work expands current knowledge and builds on the limited longitudinal investigations currently 
available in FTD, as well as providing valuable information about the potential of fully automated neuroimaging 
biomarkers for sporadic and genetic FTD trials.   
1. Introduction 
The term ‘frontotemporal dementia’ (FTD) refers to a heterogeneous 
spectrum of clinically, genetically and pathologically diverse neurode-
generative disorders. Clinically, people present with either predominant 
changes in behaviour, social conduct and personality (behavioural 
variant, bvFTD), or language impairment (primary progressive aphasia, 
PPA). PPA can be further divided into three main subtypes, semantic 
variant (svPPA), non-fluent variant (nfvPPA) and logopenic variant 
(lvPPA) (Gorno-Tempini et al., 2011). In addition, a subgroup of people 
that do not fulfil the current diagnostic criteria for the three canonical 
PPA subtypes is recognised, referred to here as PPA not otherwise 
specified (PPA-NOS) (Marshall et al., 2018; Rohrer et al., 2010b). 
Genetically, FTD is a highly heritable set of disorders, with 
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approximately a third of patients exhibiting an autosomal dominant 
form (Greaves and Rohrer, 2019; Rohrer and Warren, 2011). Mutations 
in the microtubule-associated protein tau (MAPT) and progranulin 
(GRN) genes or a hexanucleotide expansion in the chromosome 9 open 
reading frame 72 (C9orf72) gene are the major contributors (Rohrer 
et al., 2009; Warren et al., 2013). Pathologically, neuronal inclusions 
containing abnormal forms of tau or TAR DNA-binding protein 43 (TDP- 
43) are the key forms associated with FTD, with the latter classified into 
four subtypes TDP-43 Type A – D (Lashley et al., 2015; Mackenzie et al., 
2011, 2010; Seelaar et al., 2010). 
Whilst there are no treatments for FTD currently available, there are 
a number of candidate molecules demonstrating the promise of disease 
modification. In preparation for these trials, it is crucial to find accurate 
and sensitive biomarkers to evaluate the efficacy of these interventions 
and to help inform trial design so that they are powered to detect a 
clinically relevant change in these markers. Methods for quantifying 
brain atrophy rates from serial magnetic resonance imaging (MRI) are 
already employed as surrogate non-invasive markers in other neurode-
generative intervention trials (Cash et al., 2014; Tabrizi et al., 2019; 
Zeun et al., 2019), but have yet to be studied extensively in FTD. 
Incorporating imaging biomarkers as surrogate end-points may allow 
detection of disease-modifying effects with fewer participants than 
standard cognitive tests (Schott et al., 2010; Whitwell et al., 2015b) and 
have the potential for detecting these changes presymptomatically in 
genetic FTD (Borroni et al., 2008; Cash et al., 2018; Dopper et al., 2013; 
Lee et al., 2017; Panman et al., 2019; Papma et al., 2017; Popuri et al., 
2018; Rohrer et al., 2015). Therefore, validation within the different 
FTD subgroups is important to better ascertain their utility as we move 
towards treatments directly targeting FTD-associated pathologies. 
As a potential trial biomarker, longitudinal neuroimaging measures 
need to be indicative of the underlying pathological process, be associ-
ated with disease progression and sensitive to small changes given initial 
treatment effects are likely to be subtle. In practical terms, they should 
be relatively quick and easy to apply as well as consistently and accu-
rately measure change over serial images. Importantly, they should be 
reliable across different centres and image acquisitions because large 
trials of a rare condition like FTD will require multicentre or interna-
tional collaborations to recruit a sufficient number of individuals. A 
helpful metric to assess the utility of a potential biomarker is to calculate 
the sample size required to detect a treatment effect with sufficient 
statistical power. Good biomarkers produce lower sample sizes required 
to power a trial for shorter intervals, which would ultimately prove time- 
and cost-effective. Whilst longitudinal neuroimaging investigations are 
relatively scarce in FTD, several studies have investigated global volu-
metric change measures and reported associated sample size calcula-
tions (Gordon et al., 2010; Knopman et al., 2009; Mahoney et al., 2015; 
Pankov et al., 2016; Rohrer et al., 2012, 2008; Whitwell et al., 2015a; 
Staffaroni et al., 2019: summarised in Supplementary Table S1). The 
variability and inconsistency in these sample size estimates is likely due 
to small study cohorts capturing heterogenous patient subsets within the 
broad FTD spectrum as well as differing segmentation protocols and 
accuracy between studies. 
The labour-intensive nature of manual delineation and the issue of 
intra-rater variability limits its feasibility for application in large cohorts 
or extensive multicentre trials, and therefore considerable attention has 
been paid to the development of increasingly sophisticated methods of 
automated segmentation (González-Villà et al., 2016; Iglesias and Sab-
uncu, 2015; Shaikh and Ali, 2019). There are currently multiple freely 
available tools that are widely used in clinical research (Ashburner & 
Friston, 2005; Cardoso et al., 2015; Fischl et al., 2002; Ledig et al., 2015; 
Leung et al., 2011; Zhang, Brady, & Smith, 2001). Previous comparisons 
have tended to focus on the most commonly used fully integrated 
packages and pipelines, such as those included in Freesurfer, Statistical 
parametric mapping (SPM) and the FSL library (Johnson et al., 2017; 
Katuwal et al., 2016). 
Whilst there are different approaches and pipelines, they generally 
involve brain extraction (identifying brain from non-brain voxels on the 
scan); tissue classification (identifying grey matter (GM)/white matter 
(WM) and cerebrospinal fluid (CSF)); intensity correction (to account for 
image inhomogeneity); spatial normalisation or registration (to match 
to a template or atlas) and final labelling of regions of interest (ROIs) 
onto the unsegmented target image. Although automated segmentation 
techniques show great promise for measuring disease progression and 
may allow detection of disease-related treatment effects, it remains 
unclear as to which available methodologies are well-suited for FTD. 
Therefore, this study aims to investigate automated brain volumetry and 
global atrophy measures across the FTD spectrum, by applying a range 
of automated atrophy measures to a single, large FTD cohort. More 
specifically, it focuses on the direct head-to-head comparative perfor-
mance of these techniques in providing accurate longitudinal measures 
for potential non-invasive biomarkers in trials, including identifying 
which of the measures provides the lowest feasible sample size to detect 




Participants consisted of a consecutive retrospective cohort who had 
taken part in longitudinal FTD research studies at the University College 
London Dementia Research Centre (DRC), recruited through the 
Cognitive Disorders Clinic at the National Hospital of Neurology and 
Neurosurgery (NHNN) between 1992 and 2018. Cognitively healthy 
controls in the study were commonly partners, family members or carers 
of research participants. Participants were included if they had under-
gone at least two volumetric 3D T1-weighted MR images performed on 
the same scanner. Image pairs with less than 6 months interval were 
excluded to improve the signal-to-noise ratio of longitudinal change 
measurement (Schott et al., 2006). For the 46 individuals with multiple 
serial images, the earliest passing pair was included for analysis if, 
following visual assessment, no extensive differences in contrast and 
positioning were identified or artefacts that might preclude clear 
delineation of the brain boundary. If one of these images was not 
passable, the next earliest image was chosen to complete the pair. 
These initial inclusion criteria resulted in a longitudinal neuro-
imaging cohort consisted of 262 individuals: 184 people with FTD and 
78 healthy controls. The people with FTD had the following diagnoses: 
bvFTD (n = 66), svPPA (n = 45), nfvPPA (n = 45), lvPPA (n = 21), and 
PPA-NOS (n = 7). 34 of these had a pathogenic mutation in MAPT (n =
16), C9orf72 (n = 10) or GRN (n = 8). An additional 19 patients had 
postmortem confirmation of their underlying pathology: tau, including 
those with MAPT mutations (n = 19 total), and TDP-43, including those 
with C9orf72 and GRN mutations (n = 34 total). Supplementary 
Table S2 provides the full demographic summary for this cohort. 
The key focus of this study is the direct comparative performance of 
currently available automated segmentation and longitudinal volume 
change measures. Therefore, this original longitudinal neuroimaging 
cohort was further refined following the application of all segmentation 
and registration techniques and both cross-sectional and longitudinal 
quality control (QC). This resulted in a common subset cohort (n = 226) 
including only individuals who had no missing values for any of the 
segmentation or longitudinal pipeline measures. This ensured that the 
direct head-to-head comparison was performed on identical datasets of 
images. Supplementary Table S7 summarises where a missing value was 
due to a QC failure or failure of the automated pipeline to complete for 
each of the methods. This final common dataset consisted of 66 healthy 
controls and 160 people with FTD (Table 1): bvFTD (n = 56), svPPA (n 
= 38), nfvPPA (n = 42), lvPPA (n = 18), and PPA-NOS (n = 6). 31 of 
these had a pathogenic mutation in MAPT (n = 14), C9orf72 (n = 9) or 
GRN (n = 8). In the pathological groups there were 17 in the tau group 
and 32 in the TDP-43 group. This refined cohort was used for all analyses 
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reported in the current paper and was a representative subsample of the 
full original (n = 262) cohort (See Supplementary Table S2–S4 for the 
demographic data of the full cohort (n = 262) and annual rates of change 
for both the full (n = 262) and refined (n = 226) cohorts respectively for 
comparison). 
2.2. Image analysis 
2.2.1. Image acquisition 
MR images were acquired using several 1.5 Tesla and 3 Tesla scan-
ners (Supplementary Table S8). The majority of 1.5 T images were ac-
quired on a GE Signa scanner (General Electric Medical Systems, 
Milwaukee, Wisconsin, USA) employing a spoiled gradient-echo tech-
nique. The 3 T images were acquired on either a 3 T Siemens Trio or 
Prisma scanner (Siemens, Erlangen, Germany) both employing an 
MPRAGE sequence. Repeat images were acquired on the same scanner 
as the baseline. 
2.2.2. Whole-brain segmentation 
Six segmentation packages that are used widely in clinical research 
or employed in other neurodegenerative treatment trials were selected 
for comparison. These were: BMAPS (Brain Multi-Atlas Propagation and 
Segmentation (Leung et al., 2011)), SPM12 Segment (Ashburner and 
Friston, 2005) using MATLAB 14.1, GIF (Geodesic Information Flows) 
parcellation v3 (Cardoso et al., 2015), Freesurfer v5.3 (Fischl et al., 
2002, 2004), MALP-EM (Multi-Atlas Label Propagation with 
Expectation-Maximisation-based refinement) v2.1 (Ledig et al., 2015), 
and SIENAX (Structural Image Evaluation, using Normalisation, of At-
rophy – cross-sectional (Smith et al., 2002, 2007)) (Fig. 1) 
All images underwent an N4 bias correction for inhomogeneity 
(Tustison et al., 2010) and the segmentation pipeline applied indepen-
dently to all 524 images (262 baseline and repeat pairs). BMAPS, 
Freesurfer, GIF, MALP-EM and SPM12 Segment were all applied to the 
native space images using default or developer recommended pipelines 
and options. The SIENAX pipeline was applied to images pre-aligned to 
MNI-152 template space to ensure the FLIRT and BET stages of the 
pipeline completed successfully. This pre-registration to MNI template 
space was required as a final trouble-shooting solution to the SIENAX 
pipeline failing to complete in native space across the different scanner 
pairs uniformly on this multi-scanner cohort. A representation of the 
output for the six segmentation methods can be seen in Fig. 1. To obtain 
a single whole brain region, some methods were summed together, 
either by tissue type (GM + WM) or by merging all appropriate brain 
region labels together. 
2.2.3. Determining longitudinal rates of atrophy 
The resulting segmentations from these six automated techniques 
were used to derive seventeen indirect and direct measures of longitu-
dinal volume change as summarised in Table 2. 
For the six indirect brain volume difference measures (BMAPS_BV, 
Freesurfer_BV, GIF_BV, MALP-EM_BV, SIENAX_BV, SPM_BV), the repeat 
volume was subtracted from the baseline volume for the image pair, 
using each of the six segmentation techniques and expressed as an 






v1 – volume at baseline 
v2 – volume at repeat scan 
Δt – time interval between scans (years) 
Nine direct measures of change were investigated using the bound-
ary shift integral (BSI) (Freeborough and Fox, 1997; Leung et al., 2010; 
Prados et al., 2015), which measures the intensity profile shift at the 
brain boundary between two spatially aligned images and directly 
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Fig. 1. Representation of the image 
label outputs for the six automated 
whole-brain segmentation techniques 
on a randomly selected participant from 
the final cohort: a) BMAPS - Brain multi- 
atlas propagation and segmentations, b) 
SPM12 – Statistical Parametric Mapping 
Segment, c) GIF – Geodesic Information 
Flow, d) FS - Freesurfer, e) MALP-EM - 
Multi-Atlas Label Propagation with 
Expectation-Maximisation-based refine-
ment f) SIENAX - Structural Image 
Evaluation, using Normalisation, of At-
rophy- cross-sectional (MNI-152 space).   
Table 2 
Methods used to derive indirect and direct measures of longitudinal change in whole brain volume for each segmentation technique.  
Segmentation technique Indirect brain volume (BV) 
change measure 
Direct atrophy measure 
K-means Boundary Shift 
Integral (KBSI) 




BMAPS - Brain Multi-Atlas Propagation and 
Segmentations 
✓ ✓ ✕ ✕ 
BMPS_BV BMAPS_KBSI 
FS - Freesurfer (v5.3) ✓ ✓ ✕ ✕ 
FS_BV FS_KBSI 
GIF - Geodesic Information Flow ✓ ✓ ✓ ✕ 
GIF_BV GIF_KBSI GIF_GBSI 
MALP-EM - Multi-Atlas Label Propagation with 
Expectation-Maximisation-based refinement 
✓ ✓ ✓ ✕ 
MALP-EM_BV MALP-EM_KBSI MALP-EM_GBSI 
SIENAX - Structural Image Evaluation, using 
Normalisation, of Atrophy- cross-sectional 
✓ ✓ ✕ ✓ 
SIENAX_BV SIENAX_KBSI SIENA_PBVC 
SPM - Statistical Parametric Mapping ✓ ✓ ✓ ✓ 
SPM_BV SPM_KBSI SPM_GBSI SPM_PBVC  
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the BSI pipeline, each image and segmentation pair underwent a sym-
metric affine rigid 12 dof (degrees-of-freedom) registration to spatially 
align the baseline and follow-up inputs. The transformation parameters 
for this registration were averaged to ascertain the midpoint space. This 
has been shown to avoid bias compared to uni-directional (non-sym-
metric) transformation (i.e follow-up to baseline alignment). Once 
transformed into the midpoint space, both images underwent differen-
tial bias correction to further match intensity profiles of tissue types 
across and between the images. Volume change was measured in the 
average space between the image pairs (Leung et al., 2012). A strength 
of the BSI pipeline is that it can be applied using a variety of regional 
binary or probabilistic mask as the initial ROI (region of interest) used to 
inform the area over which the boundary shift is quantified. The whole- 
brain segmentations derived from the six segmentation methods were 
each used separately as this initial ROI input for the pipeline. To help 
account for partial volume and segmentation errors, the K-means or 
KBSI (Leung et al., 2010) performs a tissue-specific intensity normali-
zation and parameter selection for quantifying atrophy at the boundary 
informed using the binary segmentation masks. A recent development 
on this work is the generalised or GBSI, which adaptively estimates a 
non-binary ROI from probabilistic brain segmentations to allow for 
greater flexibility and accuracy in localizing and capturing atrophy 
(Prados et al., 2015). 
All six techniques produced a binary mask, which was used to 
calculate the KBSI. SPM, GIF and MALP-EM also produced probabilistic 
masks used for the additional three GBSI measures (Table 2). The BSI 
pipelines produce ml change in brain volume, which was then converted 






Δv – BSI derived change in brain volume (ml) 
The longitudinal pipelines for SIENA and SPM were also applied to 
derive the final two direct measures of volume change. The longitudinal 
SPM pipeline produces an annualised percentage brain volume change 
(Long_SPM_PBVC), whilst the percentage brain volume change calcu-







Δpc – SIENA derived change in brain volume (%) 
To ensure the integrity of the imaging data, all automated brain 
segmentations, KBSI and GBSI registrations and longitudinal SIENA and 
SPM pipeline outputs were visually assessed for errors or pipeline fail-
ures by an experienced image analyst (EG), blinded to patient and 
diagnosis. The longitudinal BSI registration review involved loading 
both baseline and co-registered repeat image, with the accompanying 
paired segmentation (BMAPS, Freesurfer, GIF, MALP-EM, SIENAX or 
SPM) into a 3D viewer that enabled switching between both images of 
the co-registered pair to assess any non-biological geometric distortion 
between timepoints that would result in an unreliable BSI. If an image 
pair failed (either due to cross-sectional or longitudinal quality control 
(QC) or for pipeline performance failures: see Supplementary Table S7), 
the participant was dropped from the final analysis. A common cohort of 
226 participants, each with a full set of 17 passing automated longitu-
dinal measures of brain atrophy, were included in the final analysis 
cohort (Table 1). 
2.2.4. Statistical analysis for comparing neuroimaging outcome measures 
All statistical analyses were performed using STATA version 14.1 
(Stata Statistical Software: College Station, TX: StataCorp LP). Baseline 
demographic variables were compared using a Kruskal-Wallis test for 
the continuous variables and a Fisher’s exact test for the categorical 
variables of sex and scanner type. Linear regression was used to compare 
the mean annualised rate of atrophy, adjusting for age, sex and scanner 
type. Controls were compared with i) the clinical subgroups, ii) the ge-
netic subgroups and iii) the pathologically-confirmed subgroups in three 
separate tests. Comparisons of the patient subgroups within each of these 
three groups was performed (i.e. comparing the three genetic sub-
groups), but comparisons of the subgroups across the clinical, genetic 
and pathology groups was not. 
Sample sizes were calculated to detect a 30% reduction in disease 
progression (as measured using annualised atrophy rate), corrected for 
the corresponding control rate of volume change for each whole-brain 
atrophy measure. These calculations assume a 1:1 randomisation into 
control and active treatment groups. This was performed as follows: 
Initially, the effect size was calculated using the mean difference 
between patients and controls,μp − μc and the standard deviation of the 






ES – Effect size 
μp – Mean annualised % change in brain volume in patients 
μc – Mean annualised % change in brain volume in controls 
σp – standard deviation of % change in brain volume in patients 
The effect size was then converted into estimates for the sample size 
per treatment arm for a trial with equal allocation ratio to have 80% 
power to detect a 30% reduction in the annualised atrophy rate for 












To perform a head-to-head comparison between methods, the ratio 
between the sample sizes was used. All combinations between each of 
the seventeen different methods was computed, resulting in a total of 
(17*16)/2 = 136 head-to-head comparisons. These comparisons were 
performed separately for the clinical, genetic and pathology subgroups. 
Bias-corrected and accelerated (BCa) bootstrapping was used to 
provide 95% confidence intervals for the sample size and ratios of 
sample sizes, with 2000 replications, stratified by diagnosis, genetic 
status and pathology patient subgroups (Carpenter and Bithell, 2000). 
To provide a better approximation to a normal distribution, the boot-
strap confidence intervals were calculated for the effect size instead of 
sample size and for the natural logarithm of the ratio of effect sizes 
instead of ratio of sample sizes. The latter was chosen because it has a 
















The upper and lower limits for the confidence intervals for the 
sample size and ratios of sample sizes were calculated by back trans-
forming the upper and lower limits of the confidence interval for the 
effect size and natural log of the ratio of effect sizes, respectively. 
3. Results 
3.1. Participants 
There were several significant differences in baseline demographics 
between healthy controls and FTD subgroups, as well as between the 
patient subgroups (bold in Table 1). In particular, there were differences 
in sex distribution, age at baseline, and age at symptom onset. Disease 
duration at baseline differed between the clinical and genetic patient 
subgroups but not between pathology subgroups. Finally, the lvPPA 
subgroup had a greater proportion of scans using 3 T vs 1.5 T image 
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Fig. 2. Mean and 95% confidence interval for annual whole-brain atrophy rate for all longitudinal measures for controls (blue) and each FTD subgroup (*Indirect _BV 
measures are bold and italiced to aid visual review). Mean and 95% confidence interval for annual whole-brain atrophy rate for all longitudinal measures for controls 
(blue) and each FTD subgroup. **Note the extended x-axis for the GRN subgroup to accommodate the substantially higher annual atrophy rates and wider BCa 
confidence intervals. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
E. Gordon et al.                                                                                                                                                                                                                                 
NeuroImage: Clinical 32 (2021) 102842
7
acquisition, compared to both controls and the other clinical FTD sub-
groups. LvPPA was described in 2004 (Gorno-tempini et al., 2004; 
Gorno-Tempini et al., 2011) resulting in higher proportion of 3 T ac-
quisitions. To account for these between group differences, age, sex and 
scanner type were included as covariates in all regression analyses. 
Fig. 2. (continued). 
E. Gordon et al.                                                                                                                                                                                                                                 
NeuroImage: Clinical 32 (2021) 102842
8
3.2. Differences in rates of whole-brain atrophy 
Fig. 2 presents the mean rates of whole-brain volume change with 
95% confidence intervals for controls and patients across all 17 longi-
tudinal measures separately for each FTD subgroup. These results 
demonstrate there was good group separation of controls and patients 
demonstrated for all longitudinal measures, with the exception of the 
indirect measures MALP-EM_BV, Freesurfer_BV and SIENAX_BV for the 
majority of clinical, genetic and pathological subgroups. Control rates of 
change (blue in Fig. 2) were relatively homogeneous across the mea-
sures with consistently low mean annualised rate of change close to 0. 
The highest standard deviations relative to mean change were for MALP- 
EM_BV and Freesurfer_BV measures. As indirect volume difference 
measures, this increased noise was due to the higher variability in the 
cross-sectional segmentation quality for these methods. Freesurfer had 
some of the highest mean-to-sd ratios in the raw baseline and repeat 
segmentation volumes, with MALP-EM segmentations consistently 
overestimating the brain boundary to include the largest amount of 
dura, as demonstrated by the substantially higher whole-brain volumes 
across all subgroups shown in Supplementary Table S3. Applying the 
direct BSI measures to both these segmentation methods substantially 
improved the mean-to-sd ratio, providing a more robust and consistent 
measure of longitudinal change. A full summary of the mean and sd 
atrophy rates for each of the 17 longitudinal measures across the 10 
Table 3 
Sample size per arm to detect a 30% treatment effect, with 80% statistical power at 5% significance level, with 95% BCa CIs. Results highlighted in blue and bold 
produced the lowest sample size for each patient subgroup. Those in green and underlined did not significantly differ from the lowest estimate. Those in black produced 
significantly higher sample sizes than these lowest values but were significantly lower than those highlighted in red and italics, which produced the highest estimates or 
where the upper limit of the 95% CI included infinite sample size because there was not a significant difference between patient and control groups in the atrophy rate.  
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patient subgroups and controls are summarised in Supplementary S4. 
In contrast to the controls, annual rates of change derived from the 
17 methods showed more heterogeneity within and between each pa-
tient subgroup. In the clinical subgroups, mean rate of annual atrophy 
across all methods was the lowest overall mean rate of 1.8 (1.6)% for the 
bvFTD subgroup, and demonstrated the lowest mean-to-sd ratio. SvPPA 
mean rates were 1.9 (1.2)%, nfvPPA showed a mean rate of 2.2 (1.5)%, 
lvPPA showed a 2.1 (1.6)% mean annual change and the PPA-NOS 
subgroup showed the highest mean rate of 2.5 (0.9)%. When consid-
ering the range of values provided by each measure within a subgroup, 
MALP-EM_BV consistently provided the lowest raw mean annual rates of 
change, with either SPM_BV or SIENA_PBVC reporting the highest 
(Supplementary Table S4). 
For the genetic subgroups, the mean annual rate derived across all 
methods was 1.5 (1.2)% for the MAPT subgroup, 1.7 (1.4)% for the 
C9orf72 subgroup, and 3.0 (2.0)% for the GRN subgroup. Mean rates 
within the pathology subgroups in part reflected the contributions of the 
genetic subgroup results with the Tau subgroup presenting with a mean 
rate of 1.6 (1.2)%, similar to the MAPT results, whilst the TDP-43 sub-
group reported a higher mean with 2.0 (1.6)%, reflecting the combined 
contribution of the C9orf72 and GRN individuals along with the sporadic 
patients who had come to postmortem. Again, MALP-EM_BV universally 
provided the lowest annual rates of change and either SPM_BV or SIE-
NA_PBVC consistently provided the highest mean rate of change. 
There was generally good group separation of controls and patients 
for all longitudinal measures for the clinical, genetic and pathological 
FTD subgroups as presented in Fig. 2. Results were similar after 
adjusting for age, sex and scanner type in the linear regression analysis. 
These analyses demonstrated there were highly significant differences 
(p less than 0.001) between all clinical, genetic and pathology patient 
subgroups and controls for almost all longitudinal measures, with the 
exception of the indirect measure using MALP-EM_BV, SIENAX_BV and 
Freesurfer_BV (Supplementary Table S6 provides the full regression 
results). 
3.3. Sample size results and comparison of techniques 
Table 3 reports the sample size per arm required by each of the 17 
atrophy measures to detect a 30% reduction in annualised atrophy rate 
for treatment versus control (with 80% statistical power at 5% signifi-
cance level), after accounting for the rate of volume change in controls. 
The best performing longitudinal technique as determined by providing 
the smallest sample size point estimate is highlighted in blue in Table 3. 
This differed between the clinical, genetic and pathological subgroups 
but importantly, in all cases, the sample size required by this method 
was not significantly smaller than several other longitudinal measures 
(highlighted in green and underlined in Table 3), which each provided 
equivalent point estimates with overlapping 95% CI. Indirect methods 
generally had larger sample size estimates than their direct counter-
parts, suggesting application of the BSI or longitudinal pipelines pro-
duced a substantially more robust atrophy measure. Of the indirect 
measures, BMAPS, GIF and SPM segmentations performed better as 
longitudinal measures of volume change than Freesurfer, SIENA and 
MALP-EM segmentations. Direct KBSI, GBSI and PBVC measures were 
generally not significantly different to each other within each subgroup 
based on the paired comparisons (p > 0.05), although the longitudinal 
SPM pipeline (Long_SPM_PBVC) performed poorly for some of the pa-
tient subgroups. 
Sample size estimates were low and feasible across all patient sub-
groups, with the PPA-NOS subgroup providing the smallest estimate at 
25 [95% CI (11–44)] patients required per treatment arm using the GBSI 
applied to SPM segmentations (SPM_GBSI). All 17 measures provided 
consistently low estimates for this patient subgroup. The more heter-
ogenous bvFTD subgroup needed larger samples sizes to detect an 
equivalent treatment effect. The best performing technique 
(BMAPS_KBSI) in the bvFTD subgroup would require 114 individuals 
per treatment arm, whereas all other FTD patient groups required less 
than half this number using the best performing longitudinal measure. 
Sample size estimates for the lvPPA subgroup were generally higher 
than the other PPA subgroups, although still low for the best measure at 
35 [22 – 68] participants per treatment arm using the GIF_GBSI. In the 
genetic groups, the longitudinal measures generally produced larger 
sample sizes for the C9orf72 subgroup and in the TDP-43 pathology 
subgroups, with MALP-EM_BV producing the largest sample size esti-
mate of all the measures across all the subgroups. 
Overall, the methods providing the highest sample size point esti-
mates, or where the 95% confidence for sample size included infinity 
(due to effect size confidence interval including zero – see Supplemen-
tary Table S5), were the indirect measures, particularly using MALP-EM, 
SIENAX and Freesurfer segmentations. In addition, the direct 
Long_SPM_PBVC measure performed poorly in the overlapping GRN and 
TDP-43 subgroups. The overall mean rates of change were higher in the 
SIENA_PBVC compared with the other direct longitudinal measures. 
Visual assessment of all 226 longitudinal SIENA_PBVC outputs did not 
indicate any clear registration inaccuracies that would preclude them 
from inclusion or suggest the results were an unreliable overestimation 
for any pair. The direct head-to-head comparisons with SIENA_PBVC 
demonstrated that despite these higher rates, the effect and sample sizes 
did not significantly differ from the KBSI, GBSI or SPM_PBVC results for 
many of the patient subgroups, resulting in a similar overall perfor-
mance in terms of differentiating controls and patients and resulting 
sample size estimates. The BSI measures provided the lowest estimates 
or were not significantly different from the lowest estimates, and the 
indirect measures for BMAPS, SPM and GIF segmentations provided 
significantly lower estimates than indirect measures derived from the 
other segmentation methods across the patient subgroups. 
4. Discussion 
In this study we found that six fully automated segmentation tech-
niques, which are widely used in clinical research, performed well at 
delineating the brain from non-brain for each of the images (particularly 
using BMAPS, GIF and SPM techniques). Despite good segmentation 
quality cross-sectionally, there were considerable differences in longi-
tudinal performance of these techniques across the clinical, genetic and 
pathology FTD subgroups. Application of direct measures, such as the 
BSI, significantly reduced noise compared to indirectly measured vol-
ume change, as demonstrated by substantial increases in the mean-to-sd 
ratio and reduced sample size requirements for clinical trials. 
During cross-sectional QC, only four segmentations (all using the 
Freesurfer pipeline) failed due to considerable exclusion of temporal 
lobe tissue. This segmentation issue has previously been reported for 
Freesurfer in a large Huntington’s Disease (HD) study (Johnson et al., 
2017) and is a known issue in FTD given the often extensive focal 
temporal lobe atrophy evident on patient MR images. Previous cross- 
sectional comparative studies of automated segmentation techniques 
are relatively limited but have also shown that whilst techniques 
perform well at delineating structural images, there are subtle but 
important differences in accuracy and reliability. For example, Fellhauer 
and colleagues (Fellhauer et al., 2015) found that when applied to 
people with Alzheimer’s disease (AD) and mild cognitive impairment as 
well as healthy controls, Freesurfer produced the largest GM volumes 
alongside the smallest WM volumes and SPM produced the largest WM 
volumes. Scan quality was also an issue, with SPM providing the most 
accurate segmentations when image quality was poor, which is consis-
tent with the current study’s results for the bvFTD subgroup whose 
images had the most significant motion artefacts compared with the PPA 
groups and where SPM performed comparatively well. Cross-sectional 
comparative studies have also shown significant differences in seg-
mentation accuracy and reliability depending on the software version, 
operating system and workstation type (Gronenschild et al., 2012); as 
well as highlighting the importance of visual inspection of automated 
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pipelines (Iscan et al., 2015). Both of these issues were addressed in the 
current study by applying all techniques in the same working environ-
ment and extensive visual assessment to provide as unbiased a com-
parison across measures and patient subgroups as possible. Whilst 
differences in GM/dura inclusion and minor segmentation errors were 
noted across all techniques and groups, manual editing was not per-
formed to avoid any bias to the subset of images that would be chosen 
for such correction. In addition, the aim was to assess fully automated 
pipelines with the view that they could be applied by any trial site 
irrespective of whether an experienced image segmenter was available. 
Despite good segmentation quality cross-sectionally, the level of 
delineation accuracy becomes much clearer when investigating longi-
tudinal performance across both images in the scan pair. The variability 
in the indirect measures, which are derived solely from the segmentation 
volumes and do not include additional ‘direct’ information from the 
images themselves, demonstrates that even the slightest errors of addi-
tional dura or excluded brain matter can have a substantial impact on 
detection of underlying volumetric changes longitudinally. MALP- 
EM_BV consistently produced the lowest rate of annual volumetric 
change (Supplementary Tables S3 and S4). This was driven by both 
baseline and repeat images overestimating the GM boundary to include 
more dura than the other techniques, resulting in the largest and least 
accurate volumes across the subgroups. This issue has previously been 
reported in a population of HD patients and controls (Johnson et al., 
2017). The application of the BSI, even to the segmentations that were 
less accurate, significantly reduced noise as demonstrated by substantial 
increases in the mean-to-sd ratio of atrophy measured. This produced 
larger effect sizes and considerably reduced sample size estimates to 
detect a treatment effect, with clear narrowing of the 95% BCa confi-
dence intervals for these estimates. Thus, ultimately the BSI requires a 
reasonable, but not necessarily highly precise segmentation, to accu-
rately inform an estimate of where atrophy is occurring and produce a 
robust measure of anatomical change between scans. This is also clear 
when comparing the longitudinal SIENA pipeline results with those 
produced using the indirect SIENAX_BV measure, which had a relatively 
poor performance across the subgroups. The developers have previously 
reported a strong correspondence with SIENA and the BSI when 
measuring whole-brain volume change (Smith et al., 2007). This 
remained evident based on the current results, with the SIENA longi-
tudinal pipeline performing at least as well as many of the KBSI and GBSI 
atrophy measures, irrespective of initial segmentation used to inform the 
BSI algorithm. 
The number and scope of people with FTD included in the current 
cohort and the ability to perform a direct head-to-head comparison of 
techniques on an identical dataset is a key strength of this study. This 
aimed to address the issue that, to date, considerable variability and 
inconsistency of rates of change results in FTD have likely arisen from 
investigations using small cohort numbers and application of techniques 
that could not be directly compared across studies. Reported rates of 
annualised volume loss in FTD substantially vary across studies (Sup-
plementary Table S1). However, there is broad agreement that the PPA 
groups generally demonstrate faster and more homogeneous rates of 
global change than the greater heterogeneity evident in bvFTD cohorts, 
generally in the range of 2–3% annual volume loss (Chan et al., 2001; 
Gordon et al., 2010; Rohrer et al., 2008; Whitwell et al., 2015a). Annual 
rates of change reported in the current study using the best performing 
measure for each clinical subgroup also fall within this observed range, 
demonstrating greater group separation in the language variants from 
controls and lower sample sizes required to detect a putative treatment 
effect. The current study provides one of the first reports of global rates 
of atrophy in PPA-NOS patients, which demonstrated high and consis-
tent volume loss using all seventeen atrophy measures (mean 2.5 
(0.9)%). Two PPA-NOS patients had a GRN mutation, which is known to 
demonstrate particularly high rates of atrophy, and it is important to 
highlight that these initial results are based on a small cohort (n = 6). 
This caveat is particularly important when considering the resulting 
effect and sample size calculations derived from these rates of change. 
Given the small cohort size, bootstrap 95% CI’s may have had worse 
performance (e.g. lower coverage) than for the larger subgroup cohorts. 
These PPA-NOS results will need further validation in a larger cohort 
and caution is advised in interpretating these results given the current 
cohort size. 
Previous longitudinal investigations involving patients with a known 
mutation are limited but show a similar range of global volumetric 
changes, suggesting MAPT mutations are associated with a mean annual 
rate of ~ 1.6%, intermediate between those with GRN mutations, who 
exhibit the fastest rate of loss at ~ 3.5% and C9orf72 whose volumetric 
rates have been reported as the lowest at ~ 1.4% and more in line with 
people with AD (Gordon et al., 2010; Rohrer et al., 2010a; Whitwell 
et al., 2015a; Whitwell et al., 2011). Using an average of the best per-
forming direct measure, the current study reports a similar pattern of 
results, with annual atrophy rates of 1.8 (0.9)% in MAPT, 1.6 (1.1)% for 
C9orf72 and 3.1 (2.0)% for GRN patients, who conclusively exhibit the 
highest rate of change across subgroups. With currently limited longi-
tudinal data in FTD, it is reassuring these results are consistent with 
previous reports and provide additional valuable data in terms of vari-
ability in measurement and confidence intervals to better inform trial 
design and build on the current knowledge of disease progression across 
the FTD spectrum. 
Direct comparison of automated longitudinal atrophy measures has 
not previously been investigated in FTD and showed significant differ-
ences in the performance across the 10 FTD subgroups in the current 
study. Initial positive therapeutic effects may translate to small changes 
in the rate of atrophy. Given the variability of performance, the 
importance of informed neuroimaging biomarker choice will be crucial 
to improve the chance of detecting any such disease-modifying effect. 
For a trial enrolling any of the patient subgroups, application of the BSI 
(GBSI where possible) to BMAPS, GIF or SPM segmentations overall 
produced the fewest subjects needed to detect a treatment effect with 
subtle but noteworthy differences between groups (Table 3). Reassur-
ingly, estimates for the technique that performed best in each subgroup 
were low, ranging from 25 [11–44] for PPA-NOS to 114 [74–198] for the 
bvFTD group. In the genetic analysis, the GRN subgroup produced the 
lowest sample size with 35 [17–98] patients per treatment with the 
C9orf72 subgroup providing the highest but still feasible estimate of 77 
[25–378] patients required for enrolment per arm using the best 
method. Overall, the current study confirms the potential value of fully 
automated whole-brain atrophy measures as potential biomarkers 
across the FTD spectrum. Given FTD is characterised by often focal 
patterns of volume loss, similar comparative studies assessing the value 
of more regional and subcortical measures of change as potential out-
comes across the subgroups may prove similarly informative for the 
design of future sporadic and genetic FTD trials. 
The current study reported sample sizes that were not dissimilar to 
previous studies enrolling larger patient cohorts and employing the BSI 
method. However, compared with studies investigating smaller cohorts, 
the current sample sizes are considerably lower across many of the 
clinical subgroups for the best performing method. To date, only one 
study has reported global rates of change in the different genetic pop-
ulations with accompanying sample size estimates (Whitwell et al., 
2015a), applying the BSI to SPM segmentations to derive the results. The 
current study produced substantially lower estimates for the MAPT 
subgroup and equivalent sample sizes for the C9orf72 and GRN sub-
groups using this direct measure of change. Despite equivalent partici-
pant numbers, there were clear differences between the age of 
participants, disease duration and scan interval compared with the 
current study making a meaningful direct comparison difficult. How-
ever, the key results of both these previous estimates and the current 
study demonstrate the utility of direct automated longitudinal measures 
of whole-brain volume change as potential non-invasive markers for 
upcoming genetic FTD trials. 
A key aim of this study was to assess the utility of these fully 
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automated measures as potential biomarkers and this performance was 
evaluated based on sample size calculations. However, when evaluating 
biomarker choice, there are other practical factors such as ease of 
application to consider. This will be particularly relevant in multicentre 
trials of a rare disease such as FTD, where some recruitment sites may 
not have experienced image analysts to run these techniques and trou-
bleshoot when pipelines fail to complete. One SPM segmentation failed 
to complete and additional options were required to obtain the full-brain 
mask in MALP-EM. However, the SIENAX segmentation pipeline 
required considerable troubleshooting for successful completion uni-
formly across all image pairs with the same pipeline settings, with the 
final solution being a pre-alignment of all images into MNI-152 space 
prior to application of the pipeline. Given this consideration of needing 
to apply these techniques reliably, easily and repeatedly across multiple 
sites, scanners, and acquisitions regardless of available expertise at the 
scanner site, the current study suggests that SPM, GIF and BMAPS stand 
out as preferable automated segmentation techniques based on this 
dataset. 
Another important issue highlighted by the current results relates to 
reporting and interpreting of sample sizes more generally. Issues with 
the reporting of sample sizes have been previously raised in the litera-
ture, demonstrating that many articles in high-impact medical journals 
failed to provide adequate or accurate reporting (Charles et al., 2009). 
The current dataset has a number of examples of sample size estimates 
where the point estimate appears feasible but the realistic utility of these 
methods as evidenced by the potential upper 95% BCa CI limit suggests 
differently. In the lvPPA subgroup the GIF_KBSI measure provides a 
relatively low point estimate of 126 participants required per treatment 
arm. Based purely on the point estimate and the results demonstrating 
that the GIF_KBSI generally provides a robust measure of change, it 
appears this would be a reasonable biomarker choice for an upcoming 
trial enrolling these patients. However, the upper 95% BCa CI shows as 
many as 7760 participants may potentially be required to detect the 
treatment effect, demonstrating how misleading reliance on the estimate 
alone can be, particularly when sample sizes are based on limited data. 
In a genetic FTD trial enrolling participants with MAPT mutations, it 
appears both SIENA_PBVC and SPM_KBSI would be equivalent 
biomarker choices with a point estimate of 69 and 70 respectively. 
Although not as problematic as the lvPPA example, the BCa CI for SIE-
NA_PBVC is 30–368 compared with 37–155 for SPM_KBSI, demon-
strating the possibility that over twice as many participants may need to 
be recruited to power a trial using the former outcome measure. None of 
the publications summarised in the Supplementary Table S1 provided 
confidence intervals for their sample size estimates. This lack of 
reporting confidence intervals makes interpretation and comparison of 
previously published results problematic, particularly if calculations 
were based on smaller cohorts as is common in rare conditions such as 
FTD. The current data highlights the importance of including confidence 
intervals for sample size calculations as standard given that they provide 
much more realistic data to inform the design of trials, biomarker choice 
and to accurately plan recruitment. This will be essential to avoid the 
costly and ethical issues related to underpowered trials. 
Another important issue in clinical trials is the attrition rate. Here, 
sample sizes are corrected for control rates of change but do not include 
a putative attrition rate because it has yet to be established what the 
retention rate in a large FTD trial might be. This, of course, would 
depend on the severity of patients included, the treatment type, likely 
adverse effects, and the number of visits required (Grill et al., 2015; Grill 
and Karlawish, 2010), so the current results are likely to underestimate 
the final recruitment numbers required once accounting for patient 
drop-out. An important caveat to this study is that the images underwent 
QC before inclusion into the cohort. This curation naturally biases the 
sample size estimates to be lower given a trial would recruit individuals 
who may not provide a usable scan that is adequate for analysis. In 
addition, many of the participants were enrolled in ongoing longitudinal 
studies, resulting in 46 of the participants having multiple images as 
candidates for study inclusion. Whilst the authors attempted to limit any 
additional bias by including the earliest passing scans that did not differ 
considerably in quality, this additional refinement would not necessarily 
occur in a trial situation. Again, there are no published data on the 
prevalence of this pass rate in FTD; however, UCL has conducted 
extensive neuroimaging in its Longitudinal Investigation of FTD (LIFTD) 
observational study, where approximately 16% of scans failed QC at 
baseline before analysis (based on almost 300 patients enrolled, un-
published data). Importantly, most patients returned to repeat this im-
aging assessment and acquired a successful baseline scan, resulting in a 
low overall failure rate in this symptomatic FTD study. In fact, 
increasing in trials where imaging markers are primary outcomes or key 
endpoints for the analysis plan, there is an explicit requirement for a 
passing baseline scan prior to randomisation. For example in the MS- 
SMART trial ((Chataway et al., 2020) https://clinicaltrials.gov/ct2/sh 
ow/NCT01910259), the volumetric imaging was acquired twice at 
baseline, with the best-quality scan chosen for analysis on the basis of 
expert visual rating of motion and artifacts that may preclude the 
delineation of the brain, in line with the QC conducted in the current 
study. In such trials, the current estimates would be fairly representative 
of those required to power a design with similar inclusion and exclusion 
criteria. 
5. Conclusion 
The results of this study confirm that fully automated methods for 
measuring longitudinal whole-brain atrophy perform well across all 
clinical, genetic and pathology subgroups in FTD. In the current study, 
whilst the best performing techniques vary across the different sub-
groups, there are multiple techniques for each that provide small and 
feasible sample sizes to detect a disease-modifying effect on global at-
rophy rate. The direct head-to-head comparison of techniques in this 
large FTD cohort demonstrates the importance of the choice of tech-
nique depending on the patient population being enrolled or investi-
gated, which will be of value in informing biomarker choice in the 
future. In general, direct measures of change including application of the 
BSI to SPM, GIF or BMAPS segmentation outperformed the other direct 
and all indirect measures of change. Many of these segmentation and 
longitudinal pipelines worked ‘out of the box’, requiring little or no 
additional optimisation, making them ideal for application in multi-
centre FTD trials, which may include sites that do not have advanced 
image analysis expertise. 
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